Table 1 Baseline characteristics of study participants
| Â | n | Vaccinees | n | Placebo |
|---|---|---|---|---|
Gender | ||||
 Male | 32 | 32.0 % | 20 | 20.0 % |
 Female | 68 | 68.0 % | 80 | 80.0 % |
Race | ||||
 Black | 100 | 100.0 % | 99 | 99.0 % |
 Caucasian | 0 | 0.0 % | 0 | 0.0 % |
 Mixed | 0 | 0.0 % | 1 | 1.0 % |
Age | ||||
 Mean ± SD | 100 | 36.1 ± 5.6 | 100 | 36.0 ± 6.2 |
 Range |  | 21.1–45.8 |  | 19.6–45.4 |
CD4+ (cells/μL) | ||||
 Mean ± SD | 99 | 510 ± 229 | 100 | 563 ± 195 |
 Range |  | 137–1530 |  | 242–1252 |
CD4+ (%) | ||||
 Mean ± SD | 99 | 28 ± 8 | 100 | 29 ± 7 |
 Range |  | 7–49 |  | 17–42 |
HIV RNA (copies/mL) | ||||
 <40 (assay cut-off) | 94 | 95.0 % | 96 | 96.0 % |
 ≥40 | 5 | 5.0 % | 4 | 4.0 % |
Years from HIV diagnosis | ||||
 Mean ± SD | 100 | 5.0 ± 3.0 | 100 | 4.9 ± 3.3 |
 Range |  | 1.0–14.0 |  | 1.0–19.0 |
Years from cART initiation | ||||
 Mean ± SD | 100 | 3.5 ± 2.0 | 100 | 3.3 ± 2.1 |
 Range |  | 0.7–8.2 |  | 0.6–8.9 |
cART regimen | ||||
 NNRTI or NRTI-based | 97 | 97.0 % | 98 | 98.0 % |
 PI-based | 3 | 3.0 % | 2 | 2.0 % |
Previous tuberculosis | 29 | 29.0Â % | 34 | 34.0Â % |